安罗替尼+卡瑞利珠单抗+肝动脉栓塞化疗治疗晚期转移性肝细胞癌患者疗效及不良反应的效果观察  

Efficacy and Adverse Effects of Anlotinib + Carrilizumab + Hepatic Artery Embolization Chemotherapy for Patients with Advanced Metastatic Hepatocellular Carcinoma

作　　者：周文亮[1] 张世玺[1] 郭宝宁 徐兰玲 Zhou Wenliang;Zhang Shixi;Guo Baoning(Infection Department,Shangqiu City Hospital(Branch of Shangqiu First People’s Hospital),Shangqiu,Henan,476100,China)

机构地区：[1]商丘市立医院(商丘市第一人民医院分院)感染科,河南商丘476100 [2]商丘市立医院(商丘市第一人民医院分院)肿瘤科,河南商丘476100

出　　处：《黑龙江医学》2023年第14期1699-1701,共3页Heilongjiang Medical Journal

基　　金：河南省医学科技公关计划联合共建项目(LHGJ20200936)。

摘　　要：目的:探讨安罗替尼+卡瑞利珠单抗+肝动脉栓塞化疗(TACE)治疗晚期转移性肝细胞癌患者疗效及不良反应的效果。方法:选取2019年7月—2020年12月样本医院收治的30例晚期转移性肝细胞癌患者作为研究对象,按双盲法分为观察组和对照组,每组各15例。对照组予以TACE治疗,观察组予以安罗替尼+卡瑞利珠单抗+TACE治疗,比较两组患者临床疗效、不良反应率及临床指标。结果:观察组临床疗效明显优于对照组,差异有统计学意义(χ^(2)=8.971,P<0.05)。两组患者不良反应总发生率比较,差异无统计学意义(χ^(2)=0.600,P>0.05)。治疗后,观察组用胎蛋白(AFP)、血管内皮生长因子(VEGF)、基质金属蛋白酶-9 (MMP-9)水平均低于对照组,差异有统计学意义(t=12.975、4.597、7.501,P<0.05)。观察组无进展生存期、总生存期均长于对照组,差异有统计学意义(t=5.388、2.708,P<0.05)。结论:安罗替尼+卡瑞利珠单抗+TACE在晚期转移性肝细胞癌患者治疗中的可行性较高,能够改善患者血管内皮功能,提高其治疗有效性。Objective:To investigate the efficacy and adverse effects of anlotinib+carrilizumab+hepatic artery embolization chemotherapy(TACE)in the treatment of patients with advanced metastatic hepatocellular carcinoma.Methods:30 patients with advanced metastatic hepatocellular carcinoma admitted to the sample hospitals from July 2019 to December 2020 were selected for the study,and were divided into observation and control groups according to the double-blind method,with 15 cases in each group.The control group was treated with TACE,and the observation group was treated with anlotinib+carrilizumab+TACE.The clinical efficacy,adverse reaction rate and clinical indexes of patients in the two groups were compared.Results:The clinical efficacy of the observation group was significantly better than that of the control group,and the difference was statistically significant(χ^(2)=8.971,P<0.05).There was no statistically significant difference in the incidence of adverse reactions of the two groups(χ^(2)=0.600,P<0.05).After treatment,the levels of AFP,VEGF,and MMP-9 in the observation group were lower than those in the control group,and the differences were statistically significant(t=12.975,4.597,7.501,P<0.05).Progression-free survival and overall survival were longer in the observation group than in the control group,and the differences were statistically significant(t=5.388,2.708,P>0.05).Conclusion:Anlotinib+carrilizumab+TACE is more feasible in the treatment of patients with advanced metastatic hepatocellular carcinoma,improving their vascular endothelial function and enhancing their therapeutic effectiveness.

关 键 词：安罗替尼 卡瑞利珠单抗 肝动脉栓塞化疗 晚期 转移性 肝细胞癌 疗效 不良反应 

分 类 号：R735.7[医药卫生—肿瘤]